Treatments for COVID-19 with Dr. Clotet and Dr. Fuster

Alma, the social network is a new way of talking about the social. With attitude and optimism. From diversity. And based on the stories of the ”la Caixa” Foundation. Find and read other news like this here.

Are there treatments that are working successfully to treat COVID-19 patients? Are new drugs expected to be authorized shortly? How does the disease affect people with previous cardiovascular pathologies? These and other questions will be raised in the ”la Caixa” Health In Sight debate, which will be broadcast on streaming on September 22 under the title “The success of treatments already available for patients with COVID-19”.

In it, leading doctors and researchers who receive grants from the ”la Caixa” Foundation Research Program, Dr. Bonaventura Clotet and Dr. Valentín Fuster, moderated by the journalist Josep Corbella, will give the answers (so far known) to the great questions posed by the greatest health challenge we face on a global scale. To follow the debate, you can register here.

Words like remdesivir, anticoagulants or dexamethasone they have crept into our daily vocabulary more than we could have imagined. And is that Any small progress to overcome the global pandemic that COVID-19 has plunged us into is seen as a ray of hope.

However, as any good scientist always says, there is more progress in raising questions than finding answers. And the question, in this case, is related to “The success of treatments already available for patients with COVID-19”. This is the title of the debate organized by the ”la Caixa” Foundation, which will be held on Tuesday 22, starting at 7 pm, which will be broadcast live on the Youtube channel of the ”la Caixa Foundation”And to which you can now register here.

It will be attended by Dr. Bonaventura Clotet, head of the Infectious Diseases Service of the Germans Trias i Pujol Hospital in Badalona and director of IrsiCaixa, and Valentín Fuster, general director of the National Center for Cardiovascular Research (CNIC) in Madrid and director of the Cardiovascular and Physician-in-Chief from Mount Sinai Medical Center in New York.

Both experts agree that the time factor is crucial, both to develop an effective vaccine as to know more about this virus and treat it more optimally thanks to the advances of the investigation. Fuster, in fact, remarks that this pandemic is “a call to the humility of the scientific community, because we hardly know anything about this virus.”

The prestigious cardiologist compares it with the knowledge of his field, cardiology, which has proven to be one of the Achilles heels in patients with severe disease. “COVID-19 is a pathology in which blood clots play an important role. We have made observations in more than 5,000 patients who have been treated with a certain type of anticoagulant that reduces mortality. The results with these treatments are very encouraging”, He comments.

Anticoagulants are not the only field in which treatments are being developed to slow the progression of the disease, especially towards more serious states. “Remdesivir is an inhibitor of the virus within the cell that has been shown to be effective in the early stages of the disease.. And dexamethasone administered early is also very effective in reducing the need for intubations and mortality, ”says Dr. Bonaventura Clotet.

The director of IrsiCaixa adds that “the death rate will drop for sure, because treatments are being used more effectively and earlier. Also, people are diagnosed in earlier stages. We will be able to reduce mortality because the treatment is earlier and more effective ”.

The big question, the one that is on the lips of a large part of the citizenry every day is: “when will the vaccine be?” “We are continually learning about COVID-19. And we will win, with time and patienceia. It is true that different vaccines are being developed, but to think that it will be the solution… I think we are still far away, because we do not know what the side effects of these vaccines can be. We have to be hopeful, but we know very little, ”says Dr. Fuster.

For her part, Clotet fully trusts a vaccine, although she knows that “it is not easy to find the one that works in the different scenarios that COVID-19 can present. What is being tested are vaccines that include the protein S of the virus and we are going to see how long the neutralizing antibodies last and how many doses will have to be administered. Vaccines have eradicated many diseases that were very serious. And they are risk-free despite the existence of movements that question them”.

Clotet focuses on another tool, in this case technological, which will help slow the advance of new waves of SARS-CoV-2 infection. “We are working together with the Mobile World Congress and the Generalitat de Catalunya to create the epidemiological observatory. This observatory will make it possible to foresee the spread of new outbreaks and establish a more adequate management of epidemics like the one we are experiencing at the moment ”. The key word in this compendium of efforts is artificial intelligence, “A tool that will be very useful to us to create this epidemiological observatory”, comments Clotet.

And it is that they already told us when we were little, that prevention is better than cure.